{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:10:13Z","timestamp":1761235813995},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.031","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T15:46:04Z","timestamp":1485099964000},"page":"1175-1183","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers"],"prefix":"10.1016","volume":"35","author":[{"given":"Limin","family":"Wijaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Y.L.","family":"Tham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne F.Z.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail W.L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny G.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.031_b0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4065\/79.5.671","article-title":"Overview, prevention, and treatment of rabies","volume":"79","author":"Hankins","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2016.12.031_b0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(04)15792-9","article-title":"Rabies and other lyssavirus diseases","volume":"363","author":"Warrell","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.031_b0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11908-012-0268-2","article-title":"Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts","volume":"14","author":"Feder","year":"2012","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2016.12.031_b0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1474-4422(02)00041-8","article-title":"Human rabies: a disease of complex multispecific mechanisms and diagnostic challenges","volume":"1","author":"Hemachudha","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0025","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.031_b0030","unstructured":"WHO. WHO Rabies Factsheet. Available at: <http:\/\/www.who.int\/mediacentre\/factsheets\/fs099\/en\/>."},{"key":"10.1016\/j.vaccine.2016.12.031_b0035","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","article-title":"Rabies vaccines: WHO position paper\u2013recommendations","volume":"28","author":"Publication","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.031_b0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/cid\/cis384","article-title":"Rabies postexposure prophylaxis in routine practice in view of the new Centers for Disease Control and Prevention and World Health Organization recommendations","volume":"55","author":"Uwanyiligira","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.031_b0045","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2005.01.030","article-title":"Rabies control in South and Southeast Asia","volume":"23","author":"Wilde","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.031_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00531-14","article-title":"Zagreb regimen, an abbreviated intramuscular schedule for rabies vaccination","volume":"22","author":"Ren","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0055","unstructured":"S W. A new PIKA adjuvant rabies vaccine. J Appl Prev Med 2010;16(1):1\u20134."},{"key":"10.1016\/j.vaccine.2016.12.031_b0060","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2016.12.031_b0065","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1128\/JVI.00596-10","article-title":"An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice","volume":"84","author":"Lau","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0070","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.vaccine.2008.12.048","article-title":"A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic","volume":"27","author":"Lau","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.031_b0075","first-page":"113","article-title":"PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA","volume":"4","author":"Shen","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01378634","article-title":"A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects","volume":"131","author":"Lin","year":"1993","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","article-title":"A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies","volume":"489","author":"Zhang","year":"2016","journal-title":"Virology"},{"issue":"994","key":"10.1016\/j.vaccine.2016.12.031_b0090","first-page":"22","article-title":"Cell Rabies vaccine research and production progress","volume":"1","author":"Vero","year":"1994","journal-title":"Prog Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0095","unstructured":"Dutta AK, Weinberger C, Houillon G, Rassouli A. Worldwide experience with a purified vero-cell-culture rabies vaccine; 2008. <http:\/\/rabiesorg in\/rabies-journal\/rabies-08-1\/WorldWidehtm 2008>."},{"key":"10.1016\/j.vaccine.2016.12.031_b0100","first-page":"554","article-title":"Establishment and application of hybridomas producing anti-rabies nucleoprotein McAb and fluorescent antibody virus neutralization test","volume":"29","author":"ZHANG Shou-feng","year":"2006","journal-title":"Chin J Lab Med"},{"key":"10.1016\/j.vaccine.2016.12.031_b0105","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/JVI.77.3.2081-2092.2003","article-title":"Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load","volume":"77","author":"Addo","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0110","doi-asserted-by":"crossref","first-page":"10986","DOI":"10.1128\/JVI.01124-08","article-title":"Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire","volume":"82","author":"Tan","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.12.031_b0115","unstructured":"Zhang S, Qian F. CPC for DC and P. Summary report on comparison experiment of street rabies virus post-exposure treatment by PIKA adjuvant rabies vaccine, commercial rabies vaccine, and human rabies immune globulin."},{"key":"10.1016\/j.vaccine.2016.12.031_b0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol Cell Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T22:58:34Z","timestamp":1536101914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X16312567"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}